Plain-English translation of NCT05432804 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether adding a new medication called to your standard chemotherapy () can help treat glioblastoma that has come back after your first round of treatment. The study has two parts: first, doctors find the safest dose of the medication combination, then they compare it to standard chemotherapy alone to see if the new treatment works better.
Glioblastoma is an aggressive brain tumor, and when it returns after initial treatment, it becomes harder to treat and patients often have fewer good options. This trial is exploring whether adding this new medication to standard chemotherapy can improve survival and control the tumor better than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
If you join, you'll take chemotherapy pills by mouth for 5 days, then receive either a placebo (inactive pill) or the new medication on specific days of each 28-day cycle. You'll have regular MRI scans of your brain to check how the tumor is responding, blood draws to monitor your health, and follow-up visits every 2 months for up to 2 years after treatment ends. The trial team will watch closely for any side effects and stop treatment if the tumor grows or if side effects become too difficult.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States